Bioventus
BVS • NASDAQ
Bioventus is a medical - devices company in the healthcare sector trading on NASDAQ, led by CEO Robert E. Claypoole, with a market cap of $602.3M.
CEORobert E. Claypoole
Next Earnings
Upcoming earnings announcement for Bioventus
Date
Tuesday, May 5, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.09
Revenue Estimate
$130.1M
Earnings History
Past 12 earnings reports for Bioventus
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Q4 2025 | $0.24Est: $0.22 | +9.1% | $157.9MEst: $154.0M | +2.5% |  10-K |
| Nov 4, 2025 | Q3 2025 | $0.15Est: $0.12 | +25.0% | $138.7MEst: $138.2M | +0.3% | 10-Q |
| Aug 6, 2025 | Q2 2025 | $0.21Est: $0.21 | 0.0% | $147.7MEst: $146.7M | +0.6% | 10-Q |
| May 6, 2025 | Q1 2025 | $0.08Est: $0.02 | +300.0% | $123.9MEst: $122.7M | +1.0% | 10-Q |
| Mar 11, 2025 | Q4 2024 | $0.15Est: $0.08 | +87.5% | $153.6MEst: $145.2M | +5.8% | 10-K |
| Nov 5, 2024 | Q3 2024 | $0.06Est: $0.03 | +100.0% | $139.0MEst: $133.2M | +4.3% | 10-Q |
| Aug 6, 2024 | Q2 2024 | $0.19Est: $0.07 | +171.4% | $151.2MEst: $137.6M | +9.9% | 10-Q |
| May 7, 2024 | Q1 2024 | $0.07Est: -$0.07 | +200.0% | $129.5MEst: $118.4M | +9.4% | 10-Q |
| Mar 12, 2024 | Q4 2023 | $0.07Est: $0.02 | +250.0% | $135.4MEst: $124.0M | +9.2% | 10-K |
| Nov 7, 2023 | Q3 2023 | $0.05Est: $0.06 | -16.7% | $120.8MEst: $120.3M | +0.4% | — |
| Aug 8, 2023 | Q2 2023 | $0.14Est: $0.03 | +366.7% | $137.1MEst: $128.9M | +6.3% | 10-Q |
| May 16, 2023 | Q1 2023 | -$0.26Est: -$0.15 | -73.3% | $119.1MEst: $116.6M | +2.1% | — |